In article <4r7ine$c6n at newsbf02.news.aol.com>, whearl at aol.com (WHearl) wrote:
>I have been following the recombinant antibody story closely, and aside
>from a small but active group of enthusists, the technology does not seem
>to be living up to expectations yet. Conventional antibodies - monoclonal
>or polyclonal - still generate proteins which have the most desirable
>characteristics for biniding to target. I would be interested in hearing
>from others who have tried the method. Is it working well for you? Do
>you get antibodies which are better than MABs?
Don't know about phage Mabs, but I guess there's still something to be
said for somatic hypermutation and selection in germinal centers...
Perhaps new phage libraries with very great complexity will work better?
___________________________________________________________
Richard R. Hardy Member, Inst. for Cancer Research
Fox Chase Cancer Center Tel: (215) 728-2463
7701 Burholme Ave. FAX: (215) 728-2412
Philadelphia, PA 19111 E-MAIL: RR_HARDY at fccc.edu
